MRNA vs REPL · rev $1.94B vs $825.7M cap
Moderna Inc (MRNA) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported MRNA revenue for 2025-12-31 was $1.94B. Net income was -$2.82B. Revenue was down 39.9% from 2024-12-31 to 2025-12-31. MRNA currently screens at market cap $24.52B.
REPL does not have a complete income-statement cache yet.
MRNA currently screens at market cap $24.52B. REPL currently screens at market cap $825.7M.
Not investment advice. Open the MRNA and REPL stock pages for the full models.
Not investment advice.